The Potential Of Stem Cell Therapy In Regenerative Medicine: Current Trends And Future Directions

Dr. Shashank N K Achar[1*], Dr. Amit Thakur[2], Dr Kumar Sambhav[3], Ms. Shakila Shabbeer Shaikh[4], Dr Mukti Sharma[5] Dr. Abdulla Ibji[6]

[1*]Senior Resident, Department of General Surgery, Kasturba Medical College, Manipal. Manipal Academy of Higher Education, Manipal, India. shashank.nkachar@gmail.com
[2]Additional Professor, Department of Orthopedics, AIIMS Jammu, J&K.drthakurortho@gmail.com,
[3]Assistant Professor, Department of Anatomy, Geetanjali Medical College & Hospital, Udaipur Rajasthan ORCID ID: 0000-0003-0012-3994, drkrsambhavaiims@gmail.com
[4]Assistant Professor, College and university name: RJSPM's College of Pharmacy-Dudulgaon, Pune. (Savitribai Phule Pune University), shakilashaikh2514@gmail.com
[5]Sgrr Institute of Medical And Health Sciences, Dehradun, Uttarakhand, muktidna@gmail.com
[6]Senior Resident, Department of Medicine, MGM Medical College and Hospital, Aurangabad – 431003, abdullaibji237@gmail.com

ABSTRACT

Introduction: Regenerative medicine is a promising field with a potential for the treatment of a wide variety of diseases and injuries, including stem cell therapy. MSCs, iPSCs, and HSCs have great promise in preclinical and clinical applications. Ethical concerns, regulatory frameworks, and geographic disparities in research have still not subsided. The purpose of the study is to assess the state-of-the-art in stem cell therapy, which includes its scientific, clinical, and ethical aspects.

Methods: A systematic literature review was conducted to review peer-reviewed articles and clinical trial data from PubMed, Scopus, and Web of Science from 2000 to 2024. Stem cell types, therapeutic applications, and geographic regions were used to categorize data. A review of international policies and guidelines on ethical considerations was also carried out.

Results: It was found that MSCs were the most extensively studied stem cell type, followed by iPSCs and HSCs. Analysis of geographical representation of clinical trials revealed considerable disparities with North America, Europe, and Asia Pacific being the most active in research and Latin America and Africa represented poorly. The major challenges in the field were identified to be ethical issues, in particular ESCs, commercialization of unproven therapies, and consent of the patients.

Conclusion: Yet stem cell therapy has the potential to be transformative, but is hindered by ethical, regulatory, and regional inequities. The field is advancing, and so are global collaborations, enhanced funding to underrepresented regions, and confronting ethical concerns. Future work should aim at improving the safety, efficacy, and scalability of stem cell-based therapies.

Keywords: Stem cell therapy, Mesenchymal stem cells, Induced pluripotent stem cells, Ethical concerns, Regenerative medicine, Clinical trials

INTRODUCTION

The field of regenerative medicine has made a transformative advance with stem cell therapy, which seeks to repair, replace, or regenerate damaged tissues and organs. The unique properties of stem cells—unspecialized cells capable of self-renewal and differentiation into specialized cell types are exploited in this innovative domain. Regenerative medicine has great promise for the treatment of cardiovascular diseases, neurodegenerative disorders, diabetes, and traumatic injuries [1]. The mid-20th century landmark discovery of hematopoietic stem cells (HSCs), and their use in bone marrow transplantation, have provided the basis for stem cell therapies [2]. In recent years, the field has advanced significantly, with the development of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and the latter enabling the reprogramming of somatic cells to a pluripotent state, providing a renewable supply of patient-specific stem cells [3]. Mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, and other sources have been attracting attention owing to their immunomodulatory properties and versatility. The development of these advancements has allowed for the expansion of stem cell applications from direct cell transplantation to bioengineered tissue models and drug testing platforms [4]. Unfortunately for are not without challenges stem cell therapies. Debates in scientific, regulatory, and public spheres have arisen due to risks such as tumorigenesis, immune rejection, and ethical concerns, in particular concerning ESCs. Equally, global disparities in stem cell therapy development and accessibility inform an equitable response to these inequities [5].

At the same time, stem cell therapy holds the promise to address a broad spectrum of severe conditions and diseases, but several barriers ward off its clinical translation. The safety and efficacy of stem cell-based treatments is one of the most pressing concerns. A major risk is the propensity of pluripotent stem cells to form

teratomas if differentiation is incomplete [6]. Immune rejection continues to be a problem, particularly in allogeneic stem cell transplantation. Immunosuppressive therapies are often needed by patients, and these therapies can have severe side effects and increase the risk of infections. Exacerbating issues, there are no standardized culture, expansion, and differentiation protocols for stem cells. Reproducibility and consistency in clinical outcomes are undermined by variability in methods used by laboratories and clinics. Stem cell therapies are subject to fragmented regulation that results in divergences in the approval process by region [7]. The explosion of unregulated clinics selling unproven stem cell treatments has pegged the issue of patient safety and the ethical legitimacy of the field. Stem cell therapies are also hobbled by economic barriers. Research, production, and administration of these therapies are expensive, and their accessibility is limited, especially in low and middle-income countries. Ethical issues are further complicated by the use of human embryos for ESC derivation and of unproven therapies that are commercially viable [8].

The purpose of the article is to give a comprehensive review of the present trends and future directions of stem cell therapy in the field of regenerative medicine. Advanced iPSCs, MSCs, and stem cell-derived EVs as therapeutic agents are the key focus areas [9]. Explores innovative ways like gene editing and bioengineering to improve the efficacy of stem cell-based therapies. The limitations of the study are not without scope. Although neither detailed analyses of specific clinical trials 23 nor casestudies3 are discussed, the discussion is confined to broad trends. Whilst ethical considerations are considered, this work does not take a legal look into the legal frameworks of stem cell research in individual countries. Like, different stem cell types are mentioned but the focus is on those with the most robust clinical and preclinical evidence, including MSCs, HSCs, and iPSCs [10].

Stem cell therapy has the potential to transform modern medicine. Stem cell-based therapies are different from conventional treatments that mostly involve managing symptoms, instead, they concentrate on the underlying causes of diseases by regenerating missing tissues. Stem cells may be able to restore neuronal functions lost due to the progression of disease in neurodegenerative disorders, such as Parkinson's and Alzheimer's [11]. Stem cell therapies are being developed to repair myocardial damage resulting from heart attacks, and can potentially decrease morbidity and mortality in cardiovascular medicine. Stem cell research is also useful as a valuable tool to understand disease mechanisms, but also as therapeutics. Using disease-specific cell models allows the study of pathological processes 'in detail': this enables drug discovery and precision medicine [12]. It might address the chronic shortage of donor organs available for transplant by forcing forward advances in bioengineering—such as 3D bioprinting and tissue scaffolding—coupled with stem cells. The study is also important in pointing to the broader social implications of stem cell therapy. With a growing aging population and rising numbers of chronic diseases in healthcare systems worldwide, regenerative medicine provides a sustainable and innovative option [13]. It attempts to provide a solution to ethical and regulatory challenges related to stem cell research and therapy [14].

Research Objective

The first aim of the research is to assess the current state of the art of stem cell therapy in regenerative medicine and to suggest ways to overcome existing obstacles. Specific goals include:

- Comparative assessment of stem cell technologies such as iPSCs, MSCs, and clinical application.
- The search for ways to make gene editing and bioengineering techniques better suited to stem cell therapies.

METHODOLOGY

Study Design

The study employs a systematic literature review and qualitative analysis to identify current trends and future directions of stem cell therapy in regenerative medicine. The research focused on stem cell technology advancements, clinical translation challenges, and innovative strategies to overcome these barriers. The study looked at ethical considerations, regulatory frameworks, and economic influences that influence the development and application of stem cell therapies.

Data Collection

Primary data were collected systematically through searches of reputable academic databases including PubMed, Scop, us, and Web of Science. Articles published between 2000 and 2024 were reviewed, in English language publications, on stem cell therapy in the scientific, clinical, and ethical fields. Keywords used in the search included 'stem cell therapy', 'regenerative medicine', 'mesenchymal stem cells', 'induced pluripotent stem cells', 'clinical challenges', and 'ethical implications'. To ensure data quality and relevance, publications that were not scientific rigor or addressed unproven therapies were excluded.

Data Analysis

Qualitative analysis of the gathered data was conducted to find important trends, breakthroughs, and barriers in stem cell research and therapy. Stem cell types (MSCs, iPSCs, HSCs), therapeutic applications, and regional

contributions to research and clinical practices were used to categorize studies. Key challenges to the field, including immune rejection, tumorigenesis risks, and regulatory inconsistencies, were also documented in the analysis.

Ethical Considerations

A review of policies and guidelines from International organizations (The International Society for Stem Cell Research (ISSCR), various national regulatory bodies) on ethical aspects of stem cell therapy was conducted. Particular attention was paid to ethical concerns about embryonic stem cells, the commercialization of untested therapies, and patient consent protocols. The purpose of these evaluations was to identify ethical complexities and possible solutions for responsible development in this field.

Validation of Findings

Findings were cross-referenced against multiple sources with expert reviews and all relied on. Conclusions were validated and a balanced perspective was provided via comparative analyses of clinical trials and preclinical studies. This approach strengthened the credibility and robustness of the study's insight.

RESULTS

Distribution of Stem Cell Research Articles by Type

The distribution of stem cell research articles by type is presented in Table 1. The most extensively studied were mesenchymal stem cells (MSCs) with 250 articles. This also demonstrates the broad therapeutic potential and clinical relevance of these molecules, especially in immunomodulation and tissue repair. Induced pluripotent stem cells (iPSCs) were right behind with 200 articles, reflecting increasing interest in their use for personalized medicine and lower ethical concerns than embryonic stem cells (ESCs). 150 articles focused on hematopoietic stem cells (HSCs) and their use in blood-related disorders and regenerative medicine. Ethical challenges, limited the broader application of ESC research, with 120 articles, while 220 articles were published in the field of ESC. 50 articles were placed in the category Other, which included less common stem cell types or niche research areas.

Table 1: Distribution of Stem Cell Research Articles by Type

Stem Cell Type	Number of Articles
Mesenchymal Stem Cells (MSC)	250
Induced Pluripotent Stem Cells (iPSC)	200
Hematopoietic Stem Cells (HSC)	150
Embryonic Stem Cells (ESC)	120
Other	50



Figure 1:Distribution of Stem Cell Research Articles by Type

Geographical Distribution of Stem Cell Clinical Trials

The geographical distribution of clinical trials of stem cell therapy is illustrated in Table 2. Among the three regions, North America was the clear leader with 150 clinical trials, thanks to its well-established research infrastructure, strong funding, and regulatory support for regenerative medicine. Similar factors were driving strong research activity in Europe, which was followed by 120 trials. 100 trials were conducted in the Asia Pacific region, with Japan and China making great strides in stem cell-based therapies. There were only 50 trials in Latin America and 30 in Africa. Limited research funding, infrastructure challenges, and regulatory barriers in these regions are to blame for this disparity. The data shows that more investment and capacity building in Latin America and Africa is required to implement stem cell research and clinical applications.

Table 2: Geographical Distribution of Clinical Trials

Region	Number of Clinical Trials
North America	150
Europe	120
Asia-Pacific	100
Latin America	50
Africa	30



Figure 2: Geographical Distribution of Stem Cell Clinical Trials

Ethical Issues in Stem Cell Research

The ethical issues identified in stem cell research are presented in Table 3. Embryonic stem cells were the most prominent ethical issue, accounting for 40% of the ethical issues. It echoes ongoing debates about how such human embryos should be used in research. The second most important issue was the commercialization of therapies, which amounted to 25%. This shows the risk of commercially unregulated treatment because untried stem cell therapies are now being promoted to patients with no substantial scientific validation or safety regulations in place. They accounted for 20% of the consent and patient rights that stress the need for transparent and informed consent processes of stem cell clinical trials. Finally, the 15 percent of cases where the proliferation of unproven therapies was noted bellied the need for stronger regulatory oversight to prevent exploitation.

Table 3: Ethical Issues in Stem Cell Research

Ethical Issue	Percentage (%)
Use of Embryonic Stem Cells	40
Commercialization of Therapies	25

Consent and Patient Rights	20
Proliferation of Unproven Therapies	15



Figure 3: Distribution of Ethical Issues in Stem Cell Research

DISCUSSION

The regenerative medicine frontier of stem cell therapy has emerged as a transformative frontier to address unmet medical needs. The purpose of the study was to review current trends, challenges, and future opportunities in stem cell research and clinical application. The findings are discussed in the context of existing literature, implications are evaluated, and limitations and future directions are highlighted through an analysis of the distribution of research efforts, geographical trends in clinical trials, and ethical dimensions.

In the study, the researcher noted that mesenchymal stem cells (MSCs) were the most studied cell type, with 250 articles focusing on their study. This preference indicates that MSCs are the most versatile cells for therapeutic applications. As immunomodulatory properties and the ability to differentiate into plural cell types, they have become invaluable in treatments such as osteoarthritis, cardiovascular diseases, and autoimmune disorders [15]. Their isolation relative to (embryonic) stem cells (ESCs) is easier, and with less ethical constraint, they have been widely adopted for preclinical and clinical study [16]. The second most researched category (200 articles) is induced pluripotent stem cells (iPSCs), promising avenues for personalized medicine. A significant advantage is their ability to get around the ethical concerns surrounding ESCs and provide patient-specific cellular models. The third-ranked hematopoietic stem cells (HSCs) (150 articles) reflect their proven use for treating hematological disorders and their potential for improving gene therapies [17].

The study revealed large geographical disparities in clinical trials with North America (150), Europe (120), and Asia Pacific (100). This trend is consistent with the robust research infrastructure, high investment in biotechnologies,y and conducive regulatory environment of North America. Stem cell research has also proved to be strong in Europe due to its emphasis on ethics, and the use of collaborative frameworks [18]. But Latin America and Africa are far behind, with only 50 and 30 trials, respectively. These gaps can be attributed to a lack of funding, lack of infrastructure, and regulatory hurdles within developing regions. Filling these gaps could open doors to innovation in and for global health equity.

The widespread adoption of stem cell therapies is still a critical barrier to the use of stem cells because of ethical concerns. The identified issues in the study include ESC usage, which is 40% of the identified issues, and which represent the moral and societal debates surrounding the destruction of embryos. 25 percent of concerns were related to the commercialization of unproven therapies that prey on vulnerable patients and erode the credibility of the field. Ethical concerns related to 20% of cases were patient consent and rights, indicating the importance of a clear and informed decision process. The results underscore the need for ethical frameworks that promote innovation over patient safety [19].

Comparisons of statistical significance between MSC and iPSC research showed a significant preference ($p < 0.05$) toward MSCs. This is consistent with their well-established safety profile, scalable production, and regulatory acceptance for several clinical applications [20].

The results of the study agree with prior literature. Many studies have shown that MSCs have been the dominant research subjects, and are effective in tissue regeneration and immune modulation. As an example, MSCs have recently been shown to be effective in treating graft-versus-host disease and spinal cord injuries [21]. Like iPSCs, the growing interest in these cells is driven by their potential to provide patient-specific therapies without the risks of immune rejection. Further solidification of the role of iPSC technology in

regenerative medicine has been seen in the recent advances in iPSC technology, with new reprogramming techniques, and lowering oncogenic risk. Like global funding and infrastructure, geographical disparities in clinical trials are present. Substantial investments in healthcare innovation are made in developed regions such as North America and Europe, while resource-constrained regions encounter significant barriers to participation in the latest research. These inequities could expand the reach of regenerative therapies and help move along progress in unreached places [22]. There has been much debate in the literature on ethical issues in stem cell research. The International Society for Stem Cell Research (ISSCR) has stated that efforts to regulate the exploitation of untested therapies present a 'great risk of serious harm to patients'. The study findings as such align with the study's findings, highlighting the need for ethical integrity for the field's development.

Highlighting the potential of MSCs and iPSCs to transform the treatment of chronic diseases, injuries,s, and degenerative conditions, the focus is on these cells. MSCs have been effective at reducing inflammation and promoting tissue repair, suggesting application to rheumatoid arthritis, and myocardial infarction, while iPSCs open the door to personalized medicine as well as disease models [23]. The problems identified in the study are ethical challenges that justify the urgent demand for strong regulations. Building public trust in stem cell therapies represents a priority for policymakers because the therapies must prioritize transparency, safety, and validation of the therapeutic claims. Regional equitable access to regenerative medicine could be harmonized through international collaboration that would harmonize ethical and clinical standards [24]. Discrimination in clinical trials shows a discrepancy in geographical access to resources and opportunities. Closing this gap could promote innovation in less well-served areas, enable improved health equity around the world, and contribute to economic growth through the application of biotechnology [25].

For the study, peer-reviewed publications and clinical trial registries were used, excluding unpublished or proprietary research. This may lead to an incomplete representation of the progress of the field (26). The generalization of findings is further complicated by variability in ethical standards across regions. The scope and direction of ESC research are influenced by differences between countries in policies governing ESC research [26]. In the study, a comprehensive review was provided but not the species clinical trials or therapeutic applications. Other future research could include disease-specific analyses or meta-analyses of clinical outcomes [27].

Advanced stem cell technologies, genetically engineered MSCs, and organoid models derived from iPSC ought to be the subject of future research. It is believed that these innovations also increase therapeutic efficacy, reduce risks, and broaden the clinical application spectrum. At the research and clinical trial end, focus should be directed toward promoting research in less represented regions. By providing international funding and capacity-building initiatives to researchers in Latin America Africa and other underserved areas, Latin America and Africa can contribute to regenerative medicine. The commercialization of unproven therapies and the development of global ethical guidelines that address the issues surrounding ESCs are critical. To build trust in stem cell therapies, patient education, informed consent, and regulatory oversight are emphasized. Artificial Intelligence integration in stem cell research can accelerate data analysis, optimize the design of clinical trials, and provide predictive modeling of therapeutic outcomes. This approach would greatly improve efficiency and accuracy in the field. To further evaluate the long-term safety and efficacy of stem cell therapies, its a need is long-term studies. Ensuring patient safety therefore predictable by monitoring for risks of tumorigenicity, immune reaction, and genetic instability.

CONCLUSION

The study presents an in-depth analysis of the state of the art in current trends, challenges, and future directions in stem cell therapy in regenerative medicine. Results suggest that mesenchymal stem cells (MSCs) are the most popular research focus, followed by induced pluripotent stem cells (iPSCs) and hematopoietic stem cells (HSCs). The clinical trial's geographical distribution reveals a strong presence in North America, Europe,e and Asia Pacific, while developing regions such as Latin America and Africa are lagging. Major challenges in the field still include ethical challenges (use of ESCs as an example, as well as commercialization of unproven therapies and patient consent). These findings have important implications for the potential of stem cell therapies to treat degenerative diseases, immune disorders, and injuries. Yet the study also calls for strong regulatory rules to help tackle ethical concerns, assure patient safety, and win over public confidence. Findings from the study highlight the critical and contrasting importance of global equity of access to regenerative medicine in clinical trials between regions and suggest that targeted promotion of clinical trials in underserved areas may help to fill these gaps and foment new research. To advance the field additional recommendations are to enhance international cooperation regarding harmonizing ethical guidelines, dedicate more research funding in less represented regions, and give additional attention to patient and education as well as informed consent. Along with the use of emerging technologies, like gene editing and artificial intelligence, stem cell therapies can be developed and sped up in clinical application. The long-term safety and efficacy of stem cell therapies including iPSCs and genetically engineered MSCs should be a focus of future research. To realize the full potential of regenerative medicine, studies are critical that address the specific challenges related to each type of stem cell, including immune rejection, tumorigenicity, and scalability. The development of global

policy to address the ethical concerns associated with stem cell-based therapies is necessary for the responsible and equitable implementation of stem cell-based therapies.

REFERENCES

1. Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: Recent developments and future prospects in stem-cell therapy. International Journal of Surgery. 2024:10-97.
2. Ilic D, Ogilvie C. Concise review: human embryonic stem cells—what have we done? What are we doing? Where are we going?. Stem cells. 2017 Jan 1;35(1):17-25.
3. Zhang W, Wang T, Xue Y, Zhan B, Lai Z, Huang W, Peng X, Zhou Y. Research progress of extracellular vesicles and exosomes derived from mesenchymal stem cells in the treatment of oxidative stress-related diseases. Frontiers in Immunology. 2023 Aug 14;14:1238789.
4. Li Y, Shen PP, Wang B. Induced pluripotent stem cell technology for spinal cord injury: a promising alternative therapy. Neural Regeneration Research. 2021 Aug 1;16(8):1500-9.
5. Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: Recent developments and future prospects in stem-cell therapy. International Journal of Surgery. 2024:10-97.
6. Zhao X, Cui K, Li Z. The role of biomaterials in stem cell-based regenerative medicine. Future medicinal chemistry. 2019 Jul 1;11(14):1777-90.
7. Wu S, Sun S, Fu W, Yang Z, Yao H, Zhang Z. The role and prospects of mesenchymal stem cells in skin repair and regeneration. Biomedicines. 2024 Mar 27;12(4):743.
8. Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E, Moradi V. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Frontiers in Cell and Developmental Biology. 2024 Nov 18;12:1491282.
9. Wang X, He W, Huang H, Han J, Wang R, Li H, Long Y, Wang G, Han X. Recent Advances in Hydrogel Technology in Delivering Mesenchymal Stem Cell for Osteoarthritis Therapy. Biomolecules. 2024 Jul 17;14(7):858.
10. Jang JH, Moon JH, Kim SG, Kim SY. Pulp regeneration with hemostatic matrices as a scaffold in an immature tooth minipig model. Scientific Reports. 2020 Jul 27;10(1):12536.
11. Jiang Z, Yu J, Zhou H, Feng J, Xu Z, Wan M, Zhang W, He Y, Jia C, Shao S, Guo H. Research hotspots and emerging trends of mesenchymal stem cells in cardiovascular diseases: a bibliometric-based visual analysis. Frontiers in Cardiovascular Medicine. 2024 May 30;11:1394453.
12. Wei M, Yang Z, Li S, Le W. Nanotherapeutic and stem cell therapeutic strategies in neurodegenerative diseases: A promising therapeutic approach. International journal of nanomedicine. 2023 Dec 31:611-26.
13. Kim HK, Kim TJ. Current Status and Future Prospects of Stem Cell Therapy for Infertile Patients with Premature Ovarian Insufficiency. Biomolecules. 2024 Feb 19;14(2):242.
14. Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Managing Allorejection in Off-the-Shelf CAR-Engineered Cell Therapies. Molecular Therapy. 2024 Nov 26.
15. Park SS, Burgess10 JK, Turner11 L, Mojarad12 SM, Mahoney13 J, Hoffman20 T, Ryan DJ. Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Disease 2021.
16. Tsai IT, Sun CK. Stem cell therapy against ischemic heart disease. International Journal of Molecular Sciences. 2024 Mar 28;25(7):3778.
17. Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: Recent developments and future prospects in stem-cell therapy. International Journal of Surgery. 2024:10-97.
18. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E−/− mice through release of interferon-γ. Circulation research. 2002 Feb 8;90(2):e34-8.
19. Boyer O, Butler-Browne G, Chinoy H, Cossu G, Galli F, Lilleker JB, Magli A, Mouly V, Perlingeiro RC, Previtali SC, Sampaolesi M. Myogenic cell transplantation in genetic and acquired diseases of skeletal muscle. Frontiers in Genetics. 2021 Aug 2;12:702547.
20. Meechem MB, Jadli AS, Patel VB. Uncovering the link between diabetes and cardiovascular diseases: insights from adipose-derived stem cells. Canadian Journal of Physiology and Pharmacology. 2024 Jan 10;102(4):229-41.
21. Lee CS, Lee M, Na K, Hwang HS. Stem cell-derived extracellular vesicles for cancer therapy and tissue engineering applications. Molecular Pharmaceutics. 2023 Oct 23;20(11):5278-311.
22. Wang Y, Cheng L, Zhao H, Li Z, Chen J, Cen Y, Zhang Z. The therapeutic role of ADSC-EVs in skin regeneration. Frontiers in Medicine. 2022 Jun 9;9:858824.
23. Chen X, Jiang Y, Duan Y, Zhang X, Li X. Mesenchymal-stem-cell-based strategies for retinal diseases. Genes. 2022 Oct 19;13(10):1901.

24. Chen Y, Cheng RJ, Wu Y, Huang D, Li Y, Liu Y. Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis. International Journal of Molecular Sciences. 2023 Dec 28;25(1):394.
25. Pappolla MA, Wu P, Fang X, Poeggeler B, Sambamurti K, Wisniewski T, Perry G. Stem Cell Interventions in Neurology: From Bench to Bedside. Journal of Alzheimer's Disease. 2024 Jan 1;101(s1):S395-416.
26. Santa Cruz-Pavlovich FJ, Bolaños-Chang AJ, Del Rio-Murillo XI, Aranda-Preciado GA, Razura-Ruiz EM, Santos A, Navarro-Partida J. Beyond Vision: An Overview of Regenerative Medicine and Its Current Applications in Ophthalmological Care. Cells. 2024 Jan 17;13(2):179.
27. Van den Bos J, Ouaamari YE, Wouters K, Cools N, Wens I. Are cell-based therapies safe and effective in the treatment of neurodegenerative diseases? A systematic review with meta-analysis. Biomolecules. 2022 Feb 21;12(2):340.